The developer of assays to detect drug-resistant strains of HIV has now branched into Lassa detection, and will potentially be seeking instrument partners.
Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.
The effort, called FAIRplus, commenced earlier this year with a budget of €8.2 million, funded by the Innovative Medicine Initiative.
Centene will contribute up to $100 million over 10 years to fund research into Alzheimer's disease, breast cancer, diabetes, and obesity at WashU.
The funding will enable the Institute for Genome Sciences to pursue a number of infectious disease research initiatives using omics technologies.
The projects, set to begin this year, concern prostate cancer, infectious diseases, rheumatoid arthritis, inflammatory bowel disease, heart disease, and sleep disorders.
The institute — part of the European Molecular Biology Laboratory — said it will use the new funding to increase its computing, storage, and building capacity.
Four awardees will use Intermountain's NGS One Genomic Services for projects that focus on precision medicine, clinical, and translational research.
Geisinger will use the funding to develop genomic-based approaches for detecting arrhythmogenic right ventricular cardiomyopathy to aid in early intervention.
The funding will be used to develop a platform to identify species and strains of bacteria that cannot be cultured or detected with standard methods.
The new center will focus on liquid biopsy technologies for tracking treatment response and for monitoring patients with minimal residual disease.
The RT-qPCR-based assay, which has 510(k) clearance, is designed to rapidly differentiate sepsis from systemic inflammatory response syndrome.
The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.
The money is being provided under three Genome Canada funding competitions in partnership with the Canadian federal government and other groups.
The company is developing a methylated DNA biomarker that will predict all-cause mortality risk and risk of developing certain age-related diseases.
The Human Genome Reference Program aims to build a human genome reference that better accounts for genetic diversity than the existing reference.
The firm also continues to use its methylation-specific PCR technology to develop assays for partners in the oncology space.
Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
Unveiled in September, the HuBMAP program is an open, global framework supporting efforts to build a map of cells within the adult human body.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.